RedHill Biopharma (RDHL) Shares Outstanding (Weighted Average) (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Shares Outstanding (Weighted Average) data on file, last reported at $147.6 million in Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $147.6 million, down 98.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $147.6 million (down 98.8% YoY), and the FY2025 annual result was $147.6 million, down 98.8% from the prior year.
• Shares Outstanding (Weighted Average) improved to $147.6 million in Q4 2025 per RDHL's latest filing, from $63.4 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $12.3 billion in Q4 2024 and troughed at $467908.0 in Q3 2021.
• A 5-year average of $1.1 billion and a median of $4.6 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) soared 652.92% in 2024, then slumped 98.8% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $465.3 million in 2021, then soared by 32.46% to $616.3 million in 2022, then soared by 320.45% to $2.6 billion in 2023, then surged by 375.56% to $12.3 billion in 2024, then tumbled by 98.8% to $147.6 million in 2025.
• Business Quant data shows RDHL's Shares Outstanding (Weighted Average) at $147.6 million in Q4 2025, $63.4 million in Q2 2025, and $12.3 billion in Q4 2024.